In its upcoming report, Medtronic (MDT) is predicted by Wall Street analysts to post quarterly earnings of $1.20 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $7.9 billion, representing a year-over-year increase of 2.5%.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company reveals its earni ...

报告行业投资评级 报告将Medtronic PLC的评级从Sell上调至Neutral,主要原因是对Diabetes业务的可持续性增长有了更高的确信度。[2] 报告的核心观点 1) Medtronic的Diabetes业务有望保持约4%的销售增长,这将抵消其他业务的下滑。[2][9][10] 2) Medtronic与Abbott的Libre CGM合作以及780G产品的正面反馈,增强了Diabetes业务的可持续性。[4][10] 3) 预计Medtronic的Diabetes销售在2026财年前后将实现双位数增长,高于市场预期。[17][18][19][20] 分部总结 Diabetes业务 1) Diabetes业务占Medtronic总销售不到10%,但是是其最高增长的领域之一,对整体销售增长至关重要。[2] 2) Medtronic与Abbott的Libre CGM合作以及780G产品的正面反馈,增强了Diabetes业务的可持续性。[4][10] 3) 预计Medtronic的Diabetes销售在2026财年前后将实现双位数增长,高于市场预期。[17][18][19][20] 其他业务 1) 预计Medtronic的其他业务可能会出现一些下滑,但Diabetes业务的增长可以抵消这一影响。[2] 估值 1) 我们认为Medtronic的估值可以重新评估,与其历史5年平均水平以及同行业可比公司的估值水平更为接近。[22][23][24]

Medtronic (MDT) closed the most recent trading day at $82.27, moving +1.33% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1.69% for the day. At the same time, the Dow added 1.04%, and the tech-heavy Nasdaq gained 2.43%.Shares of the medical device company have appreciated by 5.33% over the course of the past month, outperforming the Medical sector's loss of 0.57% and the S&P 500's loss of 4.78%.The investment community will be closely monitoring the perfo ...

GALWAY, Ireland, Aug. 12, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its first quarter of fiscal year 2025 on Tuesday, August 20, 2024. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's first quarter of fiscal year 2025, which ended on Friday ...

PITTSBURGH, Aug. 9, 2024 /PRNewswire/ -- Federated Hermes, Inc. (NYSE: FHI), a global leader in active investing, today announced that the Board of Trustees of Federated Hermes ETF Trust, on behalf of its portfolio, Federated Hermes MDT Large Cap Growth ETF (NYSE: FLCG), has approved a change in the fundamental policy with respect to diversification, changing from a diversified company to a non-diversified company, subject to shareholder approval. The Board of Trustees also established Aug. 19, 2024, as the ...

Medtronic Diabetes expands CGM offerings to meet more people where they are in their diabetes journey DUBLIN, Aug. 7, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval for its Simplera™ continuous glucose monitor (CGM) — the company's first disposable, all-in-one CGM that's half the size of previous Medtronic CGMs. The discreet design simplifies the insertion and wear experience, eliminating the need ...

These two are rock-solid businesses with strong dividend programs.Every corporation will face challenges and setbacks -- which will sometimes sink its stock price. That's not a good reason for long-term investors to jump ship unless, of course, there's a fundamental shift in the company's prospects.Stocks that can perform reasonably well while maintaining a positive long-term outlook may well be worth holding onto for good. Corporations in this category are common, but they do exist; two examples are Merck ...

文章核心观点 - 美敦力股价在2024年上半年表现不佳,反映了整个医疗器械行业的悲观趋势,受到严重的利润率压力 [1] - 但联储即将降息的乐观预期为投资者带来了一些缓解 [1] - 美敦力股价最近突破了50日均线,显示可能出现短期看涨趋势 [2][3] 行业和公司总结 行业概况 - 全球通胀率预计将从2023年的6.8%下降到2024年的5.9%,这在一定程度上抑制了医疗技术巨头如美敦力的下滑 [7] - 联储预计将在9月份降息,有利于缓解通胀压力,帮助美敦力提高收入、降低成本,重回高增长轨道 [8][9] 公司表现 - 美敦力在心血管、外科手术和结构性心脏等领域持续推出新产品,并扩大全球市场份额,抵消了通胀和供应链中断的影响 [11][12][13] - 公司的流动性状况良好,可以满足近期债务义务 [13] - 公司的股息收益率超过行业和板块平均水平,且派息率较高 [14] - 公司当前估值较低,股价具有一定上涨空间 [16] 潜在风险 - 中美贸易摩擦可能影响公司在中国市场的业务表现 [17][18] - 未来股息增长率可能难以维持较高水平 [19] 总结 尽管美敦力面临一些短期挑战,但凭借良好的基本面和业务策略,加上有利的宏观环境,公司仍有望实现长期增长。现有股东可继续持有,新投资者可等待股价回调后再考虑入场。[20]

Medtronic (MDT) closed the most recent trading day at $80.32, moving -0.61% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 1.08%. Elsewhere, the Dow gained 0.75%, while the tech-heavy Nasdaq added 2.64%.Coming into today, shares of the medical device company had gained 4.45% in the past month. In that same time, the Medical sector gained 0.71%, while the S&P 500 lost 0.44%.Analysts and investors alike will be keeping a close eye on the performance of Medtroni ...

•  New products double the number of Federated Hermes ETFs PITTSBURGH, July 31, 2024 /PRNewswire/ -- Federated Hermes, Inc. (NYSE: FHI), a global leader in investment management, today announced the launch of four actively managed ETFs that take a quantitative approach to stock selection. The new products offer investors another way to access the disciplined Federated Hermes MDT investment process, crafted and refined for more than 30 years and now available in an ETF structure.The new ETFs offer core and s ...